Cargando…
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
Type 2 diabetes mellitus (DM2) is characterized by excessive hepatic gluconeogenesis, increased insulin resistance and a progressive inability of pancreatic beta cells to produce sufficient insulin. DM2 evolves as a progression from normal glucose tolerance, to impaired glucose tolerance (IGT) to fr...
Autores principales: | Stafford, John M, Elasy, Tom |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291335/ https://www.ncbi.nlm.nih.gov/pubmed/17969380 |
Ejemplares similares
-
A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications
por: Behzad, Molavi, et al.
Publicado: (2007) -
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022) -
Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023) -
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
por: Mazzone, Peter J, et al.
Publicado: (2012) -
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
por: Kim, Sun Woo
Publicado: (2010)